Elsiglutide
- Generic Name
- Elsiglutide
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- 914009-84-0
- Unique Ingredient Identifier
- SC864Q40VB
- Indication
Investigated for use/treatment in diarrhea and adverse effects (chemotherapy).
- Associated Conditions
- -
- Associated Therapies
- -
Dose Finding Study in Colorectal Cancer Patients Receiving 5-FU-based Chemotherapy to Assess the Efficacy of Elsiglutide in the Prevention of Chemotherapy Induced Diarrhea (CID)
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2015-03-09
- Last Posted Date
- 2024-03-01
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 498
- Registration Number
- NCT02383810
- Locations
- 🇵🇱
Wojewódzki Szpital Zespolony im. Rydygiera, Toruń, Poland
🇧🇾Healthcare Institution Minsk City Clinical Oncologic Dispensary, Minsk, Belarus
🇷🇺State Budgetary Institution of Arkhangelsk Region "Arkhangelsk Clinical Oncology Dispensary", Arkhangelsk, Russian Federation
Proof-of-Concept Study in Cancer Patients to Assess Efficacy of Elsiglutide in Preventing Chemotherapy-Induced Diarrhea
- First Posted Date
- 2012-03-05
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- Helsinn Healthcare SA
- Target Recruit Count
- 138
- Registration Number
- NCT01543451
- Locations
- 🇧🇬
Department of Chemotherapy, Complex Oncology Center, Ruse, Bulgaria
🇧🇬Chemotherapy Department, Complex Oncology Center, Shumen, Bulgaria
ðŸ‡ðŸ‡ºPetz Aladar County Teaching Hospital, Center of Oncologic Radiology Hungary, Gyor, Hungary
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath